Feed IBRX
IB

ImmunityBio IBRX · NASDAQ

$8.31 -3.82% (-$0.33)

Market cap
$8.92B
Enterprise value
$9.66B
P/E
-
Forward P/E
-
PEG
-
P/S
53.8x
P/FCF
-
EV/EBITDA
-
ROIC
-45.0%
Gross margin
94.6%
Net margin
-598.6%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.13
Free float
10.9%

About the company

ImmunityBio, Inc. (IBRX) is a biotechnology company specializing in the development of immunotherapeutic treatment therapies for various types of cancer and infectious diseases. The company is engaged in developing innovative approaches that activate patients' immune systems and help them fight diseases. ImmunityBio develops drugs that can stimulate immune response, enhance treatment efficacy, and increase the chances of successful outcomes. With the growing research in the field of immunotherapy and the need for new treatment approaches, ImmunityBio, Inc. has the potential for sustained growth. ImmunityBio, Inc. (IBRX) shares might be an interesting choice for investors seeking involvement in the biotechnology and immunotherapeutic treatment therapies industry.

Sector

Healthcare

Industry

Biotechnology

CEO

Richard Gerald Adcock

Employees

688

Headquarters

San Diego

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.